| PCMA

Matrix Global Advisors Touts Biosimilar Interchangeability Proposal in Biden Administration Budget – SSR Health: Biosimilar Competition Leads to Significant Decline in Net Prices on Brand Humira

April 2, 2024

Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market and have advocated for policy changes that will increase generic and biosimilar uptake and put an end to brand manufacturers’ tactics to extend exclusivity on brand-name biologics. As more

Order Confirmation

May 25, 2023

Thank you for your order!

The Low Cost of Generic Tadalafil Prescription Medication

May 18, 2021

Main Information On Tadalafil Principle of Action Tadalafil is the main active ingredient of Cialis, one of the most popular drugs for erectile dysfunction (ED) today. This substance is responsible for the effect of Cialis on the male body. How

PCMA: New IQVIA Institute Report Shows Declining Net Spending on Prescription Drugs

April 19, 2018

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a new report from the IQVIA Institute that shows net prescription spending is decreasing in settings in which pharmacy benefit management (PBM) tools are widely used.

Order Failed

May 25, 2023

Your transaction failed, please try again or contact support.

Pharmacy Benefit Companies Highlight Critical Role of Making Insulin Affordable and Accessible for All Americans at Senate Hearing

May 19, 2023

Pharmacy Benefit Companies Negotiate with Big Drug Companies to Lower Prescription Drug Costs for Patients and Families Last week, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing, “The Need to Make Insulin Affordable for All Americans,”

PCMA: Drug Manufacturer Price Hikes Offset by Rebates

December 20, 2018

(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on reports that twenty-eight drugmakers are set to raise prescription drug prices in 2019: “Today’s news underscores the fact that drugmakers alone set

PCMA Responds to “Patient Right to Know Drug Prices Act” and “Know the Lowest Price Act”

March 15, 2018

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on legislation, the “Patient Right to Know Drug Prices Act” and the “Know the Lowest Price Act,” introduced today in the Senate: “We support the patient always

Gleostine Price Hike Undercuts Drugmakers’ Campaign to Deflect Blame for High Prices

January 4, 2018

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the decision to raise Gleostine’s price from $50 to $768: “The drug company’s decision to raise the price of the forty-year-old drug Gleostine by 1400% –

The Pharmacy Benefit Brief | October 2021

October 21, 2021

Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. PLEASE, JUST THE FACTS ON PHARMACY COUNTS… When it comes to

Search Results for: